4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Silexion Therapeutics Corp (SLXN) operates in the Biotechnology industry and is headquartered in Jerusalem, Israel with about 13 employees. Its market capitalization is roughly $3 million. In the fiscal year ended 2025-12-31, SLXN reported $0M in revenue and ($12M) in net income.
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($12M) | ($13M) | ($5M) | ($4M) |
| Net Income | ($12M) | ($16M) | ($5M) | ($3M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($3M) | ($4M) | ($3M) | ($2M) | ($2M) | — |
| Net Income | ($3M) | ($4M) | ($3M) | ($2M) | ($2M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $7M | $3M | $5M | $9M |
| Total Liabilities | $5M | $7M | $17M | $16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SLXN viewer.
About TickerBase · Data methodology & sources